Here ’s to 100 Years of Insulin and Science—and More to Come!
In the last year we ’ve celebrated the 100th anniversary of insulin as a treatment for diabetes. Many articles were published on this topic, providing cause for gratitude and optimism in a year that has otherwise been difficult. To conclude this celebration, the January 2022 issue ofDiabetes Care contains two fine articles. One is an historical perspective by David Harlan and colleagues (1), tracing the evolution of our understanding of insulin, the people who took part in it, and the scientific explosion stimulated by insulin-related research. The other, by Will Cefalu et al. (2), describes the proceedings of a scientif...
Source: Diabetes Care - December 28, 2021 Category: Endocrinology Source Type: research
Comment on Stempniewicz et al. Chronic Kidney Disease Testing Among Primary Care Patients With Type 2 Diabetes Across 24 U.S. Health Care Organizations. Diabetes Care 2021;44:2000 –2009
Stempniewicz et al. (1) highlight the variability and significant gaps in adherence to guideline-recommended urine albumin-to-creatinine ratio (uACR) testing in primary care. Innovation could close these gaps, as demonstrated by a home-based uACR testing program in the U.K. that combines service design and new technology to improve population health. (Source: Diabetes Care)
Source: Diabetes Care - December 28, 2021 Category: Endocrinology Source Type: research
Comment on Parente et al. The Relationship Between Body Fat Distribution and Nonalcoholic Fatty Liver in Adults With Type 1 Diabetes. Diabetes Care 2021;44:1706 –1713
With great interest we read the recent study by Parente et al. (1), in which they report a clear relationship between body fat distribution and nonalcoholic fatty liver (NAFL) in patients with type 1 diabetes. Visceral adipose tissue as measured with DXA was independently associated with NAFL (MRI assessed prevalence, 11.6%), whereas peripheral and total body fat were not. In addition, waist-to-height-ratio (WHtR) was more strongly associated with NAFL than BMI. Based on this, they state that WHtR might be an easy and inexpensive tool to screen individuals with type 1 diabetes at higher risk for NAFL. (Source: Diabetes Care)
Source: Diabetes Care - December 28, 2021 Category: Endocrinology Source Type: research
Comment on Hamblin et al. Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor –Treated Type 2 Diabetes. Diabetes Care 2021;44:e124–e126
The study on sodium –glucose cotransporter 2 inhibitor (SGLT2i) therapy by Hamblin et al. (1) advocates for increasing β-hydroxybutyrate (BHB) to 1.7 mmol/L for hyperketonemia, in contrast to our previously suggested threshold of 1.0 mmol/L (2). This change is premature, since the new cutoff is based on a nonnormally distributed data set, the risk of developing ketoacidosis is different in patients with diabetes compared with patients without diabetes, and a higher BHB threshold may increase the false-negative rate of early ketoacidosis. (Source: Diabetes Care)
Source: Diabetes Care - December 28, 2021 Category: Endocrinology Source Type: research
Response to Comment on Parente et al. The Relationship Between Body Fat Distribution and Nonalcoholic Fatty Liver in Adults With Type 1 Diabetes. Diabetes Care 2021;44:1706 –1713
We would like to thank Dr. de Vries and colleagues (1) for the interest and comments on our article in which we showed that the visceral adipose tissue, but not the peripheral or total fat tissue, is associated with nonalcoholic fatty liver (NAFL) when assessed by MRI in adults with type 1 diabetes (2). Furthermore, we showed that waist-to-height ratio (WHtR) has a stronger association with NAFL than BMI in this population. (Source: Diabetes Care)
Source: Diabetes Care - December 28, 2021 Category: Endocrinology Source Type: research
Weighing in on Type 2 Diabetes Remission
Type 2 diabetes (T2D) is a growing public health challenge that affects 422 million people and increases morbidity and mortality (1). Obesity is a major driver of the T2D pandemic (2). T2D is frequently associated with progressive decline in β-cell function in the setting of insulin resistance, necessitating escalation of pharmacotherapy that often culminates in insulin treatment (3). Weight loss can potentially reverse this trajectory and induce remission of T2D (3,4). Metabolic surgery (MS) is the most efficacious treatment for T2D remission, with its initial effects largely mediated by reduced caloric intake and weight...
Source: Diabetes Care - December 28, 2021 Category: Endocrinology Source Type: research
Comment on Shih et al. Increased Incidence of Pediatric Type 1 Diabetes With Novel Association With Coxsackievirus A Species in Young Children but Declined Incidence in Adolescents in Taiwan. Diabetes Care 2021;44:1579 –1585
We applaud Shih et al. (1) for using enterovirus (EV) infection as a time-dependent covariate and time to type 1 diabetes (T1D) onset as the outcome to examine the relationship between EV infection and the incidence of T1D. The authors excellently obtained isolation numbers for the top five EV serotypes from a nationwide laboratory surveillance system of the Taiwan Centers for Disease Control (Taiwan CDC) to correlate the Taiwan T1D incidence with different species of EV infection. However, we have some concerns regarding using the decreasing trend of EV infection to explain the decreasing trend of T1D incidence in Taiwane...
Source: Diabetes Care - December 28, 2021 Category: Endocrinology Source Type: research
8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes —2022
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA ’s cl...
Source: Diabetes Care - December 16, 2021 Category: Endocrinology Source Type: research
Index
A1C, S4,S18 –S19advantages of, S18and cardiovascular disease outcomes, S88 –S89confirming diagnosis with, S19correlation with BGM, S84in diagnosis of adults, S18 –S19in diagnosis of children, S18 –S19differences in children, S84 –S85hemoglobinopathies and, S19limitations, S84other conditions affecting, S19point-of-care assays, S4, S18in prediabetes, S23in pregnancy, S235race/ethnicity and, S19, S84 –S85recommendations, S19setting and modifying goals for, S89 –S90 (Source: Diabetes Care)
Source: Diabetes Care - December 16, 2021 Category: Endocrinology Source Type: research
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes —2022
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA ’s cl...
Source: Diabetes Care - December 16, 2021 Category: Endocrinology Source Type: research
3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes —2022
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA ’s cl...
Source: Diabetes Care - December 16, 2021 Category: Endocrinology Source Type: research
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes —2022
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA ’s cl...
Source: Diabetes Care - December 16, 2021 Category: Endocrinology Source Type: research
7. Diabetes Technology: Standards of Medical Care in Diabetes —2022
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA ’s cl...
Source: Diabetes Care - December 16, 2021 Category: Endocrinology Source Type: research
Summary of Revisions: Standards of Medical Care in Diabetes —2022
(Source: Diabetes Care)
Source: Diabetes Care - December 16, 2021 Category: Endocrinology Source Type: research
17. Diabetes Advocacy: Standards of Medical Care in Diabetes —2022
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA ’s cl...
Source: Diabetes Care - December 16, 2021 Category: Endocrinology Source Type: research
